Despite the therapeutic success of monoclonal antibodies (mAbs), early identification of
developable mAb drug candidates with optimal manufacturability, stability, and delivery
attributes remains elusive. Poor solution behavior, which manifests as high solution viscosity
or opalescence, profoundly affects the developability of mAb drugs. Using a diverse dataset
of 59 mAbs, including 43 approved products, and an array of molecular descriptors
spanning colloidal, conformational, charge-based, hydrodynamic, and hydrophobic …